The effect of D2E7, a new human anti-TNFα monoclonal antibody, on the oxidative burst of PMN in patients with RA.

被引：0
|
作者：
den Broeder, AA
Wanten, GJA
van Riel, PLCM
Kroot, EJ
Naber, THJ
Barrera, P
机构：
[1] Univ Nijmegen Hosp, Dept Rheumatol, NL-6500 HB Nijmegen, Netherlands
[2] Univ Nijmegen Hosp, Dept Gastroenterol, NL-6500 HB Nijmegen, Netherlands
来源：
ARTHRITIS AND RHEUMATISM | 1998年 / 41卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
150
引用
收藏
页码：S57 / S57
页数：1
相关论文
共 50 条
  • [21] Efficacy and tolerability of weekly subcutaneous injections of the fully human anti-TNF-antibody D2E7 in patients with rheumatoid arthritis -: Results of a phase I study
    Schattenkirchner, M
    Krüger, K
    Sander, O
    Rau, R
    Kroot, EJ
    van Riel, PLCM
    van de Putte, L
    Fenner, H
    Kempeni, J
    Kupper, H
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S57 - S57
  • [22] TNF blockade by the fully human monoclonal antibody, adalimumab (D2E7), in the ARMADA trial results in decreases in serum matrix metalloproteinase (MMP) levels along with impressive clinical improvement in refractory RA patients.
    Furst, D
    Keystone, E
    Weinblatt, M
    Kavanaugh, A
    Weisman, M
    Fischkoff, S
    Chartash, E
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S215 - S215
  • [23] Effect of a fully human anti-TNFα monoclonal antibody on the local and systemic expression of TNFα and IL-1β.
    Barrera, P
    Joosten, LAB
    den Broeder, AA
    van de Putte, LBA
    van den Berg, WB
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S75 - S75
  • [24] Adalimumab (D2E7), a fully human anti-TNF-α monoclonal antibody, improved health-related quality of life in patients with active rheumatoid arthritis despite concomitant methotrexate therapy.
    Wellborne, F
    Keystone, EC
    Kivitz, A
    Greenwald, M
    Teoh, L
    Fischkoff, S
    Chartash, E
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S518 - S518
  • [25] Safety and efficacy of adalimumab (D2E7), a fully human Anti-TNF-α monoclonal antibody, given in combination with standard antirheumatic therapy:: Safety trial of adalimumab in rheumatoid arthritis (STAR).
    Furst, DE
    Schiff, M
    Fleischmann, R
    Birbara, C
    Strand, V
    Compagnone, D
    Chartash, E
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S572 - S572
  • [26] Long-term efficacy and tolerability of multiple i.v. doses of the fully human anti-TNF-antibody D2E7 in patients with rheumatoid arthritis.
    Rau, R
    Sander, O
    den Broeder, A
    van Riel, PLCM
    van der Putte, L
    Krüger, K
    Schattenkircher, M
    Fenner, H
    Lassmann, A
    Kupper, H
    Kempeni, J
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S55 - S55
  • [27] Serum Markers Associated with Clinical Response Measures in Rheumatoid Arthritis Patients Treated with Golimumab, a New Human Anti-TNFα Monoclonal Antibody
    Visvanathan, Sudha
    Rahman, Mahboob
    Elashoff, Michael
    Wagner, Carrie
    CLINICAL IMMUNOLOGY, 2009, 131 : S77 - S77
  • [28] Long-term treatment with the fully human anti-TNF-antibody D2E7 slows radio-graphic disease progression in rheumatoid arthritis.
    Rau, R
    Herborn, G
    Sander, O
    van de Putte, LBA
    van Riel, PLC
    den Broeder, A
    Schattenkirchner, M
    Wastlhuber, J
    Rihl, M
    Fenner, H
    Kempeni, J
    Kupper, H
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S400 - S400
  • [29] Subgroup analyses show consistent clinical benefit in the attract trial:: Anti-TNFα monoclonal antibody, infliximab, in RA patients on methotrexate.
    Kavanaugh, A
    Maini, R
    Breedveld, F
    Smolen, J
    Kalden, J
    Lipsky, P
    Furst, D
    St Clair, W
    Schaible, T
    Harriman, G
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S78 - S78
  • [30] Efficacy and safety of the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis:: a 12 week, phase II study
    van de Putte, LBA
    Rau, R
    Breedveld, FC
    Kalden, JR
    Malaise, MG
    van Riel, PLCM
    Schattenkirchner, M
    Emery, P
    Burmester, GR
    Zeidler, H
    Moutsopoulos, HM
    Beck, K
    Kupper, H
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (12) : 1168 - 1177
12345